Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension

NCT03309592 PHASE4 WITHDRAWN

The purpose of this study is to evaluate the efficacy and safety of the combination of ambrisentan and tadalafil in reducing mPAP to below 35mmHg in patients with moderate to severe Portopulmonary Hypertension (POPH) as a means to candidacy for liver transplantation.

Details

Lead sponsor	Ochsner Health System
Phase	PHASE4
Status	WITHDRAWN
Start date	Thu Oct 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Nov 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Portopulmonary Hypertension
• Pulmonary Hypertension
• Cirrhosis, Liver

Interventions

• Ambrisentan Pill
• Tadalafil Pill

Countries

United States